uniQure (NASDAQ:QURE) Given Buy Rating at Chardan Capital

Key Points

• Chardan Capital has reaffirmed a "buy" rating for uniQure's stock with a price target of $35.00, indicating a potential upside of 115.25% from its previous close.
• uniQure recently announced a quarterly EPS of ($0.69), surpassing analysts' expectations, with revenues reported at $5.26 million.
• The stock currently has an average consensus rating of "Buy" with a price target of $37.45, supported by multiple analysts' positive ratings.

uniQure (NASDAQ:QURE - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Chardan Capital in a report released on Friday,Benzinga reports. They currently have a $35.00 price target on the biotechnology company's stock. Chardan Capital's target price would suggest a potential upside of 115.25% from the company's previous close.

Several other analysts have also commented on the company. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Cantor Fitzgerald set a $47.00 price target on uniQure in a research note on Wednesday, July 30th. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of uniQure in a research note on Thursday, May 29th. Finally, Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target on the stock in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $37.45.

uniQure Trading Up 3.2%

Shares of uniQure stock opened at $16.26 on Friday. uniQure has a 1 year low of $4.45 and a 1 year high of $19.18. The company's fifty day simple moving average is $14.62 and its 200-day simple moving average is $13.66. The company has a market cap of $892.19 million, a price-to-earnings ratio of -4.15 and a beta of 0.11. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. The business had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, sell-side analysts expect that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In related news, insider Jeannette Potts sold 4,670 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the sale, the insider owned 115,073 shares in the company, valued at approximately $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 3,336 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $48,205.20. Following the completion of the sale, the director owned 56,879 shares of the company's stock, valued at $821,901.55. This represents a 5.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock valued at $322,426 over the last ninety days. Company insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

Several large investors have recently modified their holdings of the business. Vestal Point Capital LP grew its holdings in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after buying an additional 1,767,572 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after buying an additional 101,598 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock worth $38,345,000 after buying an additional 535,163 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of uniQure during the second quarter worth about $29,217,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after buying an additional 1,491,486 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.